Back to top
more

QuidelOrtho (QDEL)

(Real Time Quote from BATS)

$40.01 USD

40.01
179,102

+0.32 (0.81%)

Updated Apr 26, 2024 12:27 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (140 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Can QuidelOrtho (QDEL) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

QuidelOrtho (QDEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

3 Reasons to Add QuidelOrtho (QDEL) Stock to Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

Walgreens Boots (WBA) Q3 Earnings Top Estimates, Revenues Miss

by Zacks Equity Research

Walgreens Boots (WBA) reports better-than-expected Q3 earnings, with robust sales contributions from the International and Walgreens Health segments.

Zacks.com featured highlights include Boyd Gaming, Lithia Motors, Everest Re Group, Jones Lang LaSalle and QuidelOrtho

by Zacks Equity Research

Boyd Gaming, Lithia Motors, Everest Re Group, Jones Lang LaSalle and QuidelOrtho are part of Zacks Screen of the week article.

Swayta Shah headshot

5 Stocks With Robust Sales Growth to Beat Recession Woes

by Swayta Shah

Steady sales growth is the key to survival for a business, even during recessions. Let's check at Boyd Gaming (BYD), Lithia Motors (LAD), Everest Re (RE), Jones Lang LaSalle (JLL) & QuidelOrtho (QDEL) that are recording top-line growth.

Is the Options Market Predicting a Spike in QuidelOrtho (QDEL) Stock?

by Zacks Equity Research

Investors need to pay close attention to QuidelOrtho (QDEL) stock based on the movements in the options market lately.

Is QuidelOrtho (QDEL) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

QuidelOrtho (QDEL) Stock Jumps 3.9%: Will It Continue to Soar?

by Zacks Equity Research

QuidelOrtho (QDEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Quidel (QDEL) Down 9.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Quidel (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain QuidelOrtho (QDEL) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

Quidel (QDEL) Q1 Earnings, Revenues Surpass Estimates, Up Y/Y

by Zacks Equity Research

Quidel's (QDEL) robust performance across two of its product categories drives its first-quarter 2022 top line.

Quidel (QDEL) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Quidel (QDEL) delivered earnings and revenue surprises of 25.65% and 21.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Medical Product Stocks' Earnings May 5 Roster: MCK, CAH & PODD

by Debanjana Dey

The Medical Product companies' quarterly results are likely to reflect base business recovery. Let's see how MCK, CAH and PODD are poised ahead of their earnings releases.

Quidel (QDEL) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Quidel's (QDEL) first-quarter results are likely to reflect continued strength across its SARS-related products.

Quidel (QDEL) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Quidel (QDEL) closed at $104.52 in the latest trading session, marking a -1.32% move from the prior day.

Quidel (QDEL) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Quidel (QDEL) closed at $113.95, marking a +1.29% move from the previous day.

Quidel (QDEL) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Quidel (QDEL) closed at $112.50, marking a -0.51% move from the previous day.

Quidel Corporation (QDEL) Reports Solid Preliminary Q1 Revenues

by Zacks Equity Research

Quidel's (QDEL) revenue growth in the first quarter is likely to have been boosted by continued robust sales of its SARS-related products.

Quidel (QDEL) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Quidel (QDEL) closed at $114.15 in the latest trading session, marking a -1.17% move from the prior day.

Here's How Much You'd Have If You Invested $1000 in Quidel a Decade Ago

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Quidel (QDEL) Stock Moves -0.3%: What You Should Know

by Zacks Equity Research

Quidel (QDEL) closed the most recent trading day at $112.46, moving -0.3% from the previous trading session.

Quidel (QDEL) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Quidel (QDEL) closed the most recent trading day at $109.20, moving -1.13% from the previous trading session.

Quidel (QDEL) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Quidel (QDEL) closed at $112.17, marking a -1.71% move from the previous day.

Encompass Health's (EHC) Nationwide Hospital Count Rises to 147

by Zacks Equity Research

Encompass Health (EHC) opens a 60-bed inpatient rehabilitation hospital in Illinois, sustaining its aim to offer enhanced rehabilitation services throughout the United States.

UnitedHealth Group (UNH) Gains 38% in a Year: More Room to Run?

by Zacks Equity Research

Continued revenue growth, management optimism surrounding the Medicaid business, several contract wins, and solid cash balance continue to drive UnitedHealth Group (UNH).